Enhancing Preclinical Cell Therapy Development For Clinical Trial Readiness

In the journey toward clinical trial readiness for cell therapies, the preclinical development phase plays a pivotal role in ensuring both efficacy and safety. One of the most impactful strategies in this phase is the integration of automation into process and analytical development. By thoughtfully incorporating automation, researchers and developers can streamline workflows, enhance reproducibility, and minimize human error. A compelling example of this is the enrichment of CD34+ cells—a critical step in many cell therapy protocols—where automation led to a remarkable 40% improvement in yield. This advancement not only boosted efficiency but also significantly reduced hands-on time and lowered the risk of contamination, which are key concerns in clinical-grade manufacturing.

As the cell therapy field continues to evolve, embracing automation is no longer optional—it’s essential. Whether you're optimizing cell selection, scaling up production, or preparing for regulatory submission, discover how automation can be a transformative asset.